Ask AI
Endo and Primary Care MASH Module

CE / CME

MASH Matters: New Evidence and Its Application to Endocrinology and Primary Care Practice

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: August 01, 2025

Expiration: July 31, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161:1657-1669. 
  2. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: The need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care. 2025;48:1057-1082.
  3. Ishida K, Namisaki T, Murata K, et al. Accuracy of Fibrosis-4 index in identification of patients with cirrhosis who could potentially avoid variceal screening endoscopy. J Clin Med. 2020;9:3510.
  4. Belfort-DeAguiar R, Lomonaco R, Cusi K. Approach to the patient with nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2023;108:483-495.
  5. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-1835.
  6. American Diabetes Association Professional Practice Committee. 4. comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S59-S85.
  7. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28:528-562.
  8. Dawod S, Brown K. Non-invasive testing in metabolic dysfunction-associated steatotic liver disease. Front Med (Lausanne). 2024;11:1499013.
  9. Marks LM, Jensen T, DeGrado TR. Noninvasive testing in the diagnosis of metabolic dysfunction-associated steatohepatitis. Metab Target Organ Damage. 2024;4:28.
  10. Huang Y, Adams LA, Joseph J, et al. The ability of Hepascore to predict liver fibrosis in chronic liver disease: a meta-analysis. Liver Int. 2017;37:121-131.
  11. Madsen BS, Thiele M, Detlefsen S, et al; GALAXY consortium. PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease. Aliment Pharmacol Ther. 2021;54:699-708.
  12. Beyer C, Andersson A, Shumbayawonda E, et al. Quantitative MRI for monitoring metabolic dysfunction-associated steatotic liver disease: A test-retest repeatability study. J Magn Reson Imaging. 2025;61:1947-1955.
  13. Kaltenbach M. Why are non-invasive risk scores such as FIB-4 used in clinical practice? aasld.org/liver-fellow-network/core-series/why-series/why-are-non-invasive-risk-scores-such-fib-4-used. Accessed July 30, 2025.
  14. Wattacheril JJ, Abdelmalek MF, Lim JK, et al. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: Expert review. Gastroenterology. 2023;165:1080-1088.
  15. Wang Z, Du H, Zhao Y, et al. Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023;14:1111430.
  16. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S181-S206.
  17. Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109-121.
  18. Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: A review of current evidence. Int J Heart Fail. 2023;5:82-90.
  19. Yabut JM, Drucker DJ. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2023;44:14-32.
  20. Sanyal AJ, Newsome PN, Kliers I, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-2099.
  21. Semaglutide (Ozempic) [prescribing information]. Plainsboro, NJ: Novo Nordisk; 2025.
  22. Semaglutide (Wegovy) [prescribing information]. Plainsboro, NJ: Novo Nordisk; 2022.
  23. Saponaro F, Sestito S, Runfola M, et al. Selective thyroid hormone receptor-beta (TRβ) agonists: New perspectives for the treatment of metabolic and neurodegenerative disorders. Front Med (Lausanne). 2020;7:331.
  24. Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol. 2018;14:259-269.
  25. Harrison SA, Bedossa P, Guy CD, et al; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.
  26. Chen VL, Morgan TR, Rotman Y, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025;81:312-320.
  27. Resmetirom [prescribing information]. West Conshohocken, PA: Madrigal Pharmaceulticals, Inc; 2024
  28. Loomba R, Hartman ML, Lawitz EJ, et al; SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299-310.
  29. Sanyal AJ, Bedossa P, Fraessdorf M, et al; 1404-0043 Trial Investigators. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311-319.
  30. Francque SM, Bedossa P, Ratziu V, et al; NATIVE Study Group. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385:1547-1558.
  31. Harrison SA, Rolph T, Knott M, et al. FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond. J Hepatol. 2024;81:562-576.